OLAPARIB FOR METASTATIC BREAST CANCER AND MUTATIONS IN HOMOLOGOUS RECOMBINATION–RELATED GENES

Share

Share on facebook
Share on linkedin
Share on twitter
Share on email

The authors of this phase II trial evaluated the PARP inhibitor olaparib in the treatment of 54 patients with metastatic breast cancer (76% ER-positive/HER2-negative) and either germline mutations in non-BRCA1/2 homologous recombination–related DNA repair genes (cohort 1) or somatic mutations in BRCA1/2 or other non-BRCA1/2 homologous recombination–related genes (cohort 2). The objective response rate (ORR) in cohort 1 and cohort 2 were similar (33% and 31%), but confirmed responses were only observed in patients with germline PALB2 (ORR, 82%; PFS, 13.3 months) and somatic BRCA1/2 (ORR 50%; PFS, 6.3 months) mutations.

These findings appear to expand the patient population likely benefit from PARP inhibitors to include those with somatic BRCA1/2 and germline PALB2 mutations, in addition to germline BRCA1/2 mutation carriers.

Download here